ReviewImmunology2011
HLA-C as a mediator of natural killer and T-cell activation: spectator or key player?
Review in Immunology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed.
- High frequency of HIV mutations associated with HLA-C suggests enhanced HLA-C-restricted CTL selective pressure associated with an AIDS-protective polymorphism.Journal of immunology (Baltimore, Md. : 1950) · 2012Trial
- Predominant HLA class I associations with lupus nephritis susceptibility, histology class and reduced renal function in patients with systemic lupus erythematosus: a retrospective case-control study.Rheumatology international · 2026Article
- Integrated Host Genetics and Skin Microbiome Profiling Suggest an HLA-C-Peptostreptococcus Axis in Psoriasis.International journal of molecular sciences · 2026Article
- Donor-specific antibodies against HLA-C, HLA-DP and HLA-DQ and their implications in kidney transplantation.World journal of transplantation · 2025Review
- DNA methylation-regulated HLA-C expression modulates immune responses and metabolic alterations to influence prognosis in mesothelioma.Cancer immunology, immunotherapy : CII · 2025Article
- Computational characterization of peptide binding stability to HLA-C allotypes and its association with HIV-1 infection progression and HIV-1 related neurocognitive impairment.Frontiers in immunology · 2025Article
- Article
- Biomarkers and point of care screening approaches for the management of preeclampsia.Communications medicine · 2024Review
- HLA evolutionary divergence (HED) informs the effect of HLA-B mismatch on outcomes after haploidentical transplantation.Bone marrow transplantation · 2024Article
- Proteomic insights into breast cancer response to brain cell-secreted factors.Scientific reports · 2024Article
- Reproductive Immunology and Pregnancy 2.0.International journal of molecular sciences · 2024Article
- Article
- Biological insights from plasma proteomics of non-small cell lung cancer patients treated with immunotherapy.Frontiers in immunology · 2024Article
- Genetic immune escape landscape in primary and metastatic cancer.Nature genetics · 2023Article
- "HLA-C: evolution, epigenetics, and pathological implications in the major histocompatibility complex".Frontiers in genetics · 2023Review
- Antigen Coverage Presented by MHC Class I Has a Negative Correlation with SARS-CoV-2-Induced Mortality.Vaccines · 2022Article
- Generation of hypoimmunogenic induced pluripotent stem cells by CRISPR-Cas9 system and detailed evaluation for clinical application.Molecular therapy. Methods & clinical development · 2022Article
- Fine-mapping studies distinguish genetic risks for childhood- and adult-onset asthma in the HLA region.Genome medicine · 2022Article
- System-wide transcriptome damage and tissue identity loss in COVID-19 patients.Cell reports. Medicine · 2022Article
- Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort.PloS one · 2022Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The biochemical properties of the HLA-C antigen differ substantially from those of HLA-A and -B molecules. For this reason, HLA-C diversity and expression at the cell surface are much lower than its counterparts and in consequence HLA-C-restricted responses have been infrequently detected and described. In this review we summarise the key differences between HLA-C and other class I molecules and provide an update on natural killer and T-cell responses restricted by HLA-C. We also discuss the different clinical settings associated with HLA-C alleles which mainly consist of autoimmune disorders, cancers and chronic infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.